当前位置:首页>产品中心>单抗/多抗>Anti-Human SLC39A7 Polyclonal Antibody|抗人SLC39A7多克隆抗体(靶标:人溶质载体家族39成员7/ZIP7)

Anti-Human SLC39A7 Polyclonal Antibody|抗人SLC39A7多克隆抗体(靶标:人溶质载体家族39成员7/ZIP7)

  • 货号:RB9THD636014
  • 价格:面议
  • 点击:489
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Human
靶标HKE4, Histidine-rich membrane protein Ke4, RING5, Really interesting new gene 5 protein, SLC39A7, Solute carrier family 39 member 7, ZIP7, Zinc transporter SLC39A7, Zrt-, Irt-like protein 7
免疫原E. coli - derived recombinant Human SLC39A7 (Gly30-Thr133).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q92504
背景信息

Zinc transporter SLC39A7 is a ~50 kDa protein. Transports Zn(2+) from the endoplasmic reticulum (ER)/Golgi apparatus to the cytosol, playing an essential role in the regulation of cytosolic zinc levels. Acts as a gatekeeper of zinc release from intracellular stores, requiring post-translational activation by phosphorylation, resulting in activation of multiple downstream pathways leading to cell growth and proliferation. Has an essential role in B cell development and is required for proper B cell receptor signaling. Plays an important role in maintaining intestinal epithelial homeostasis and skin dermis development by regulating ER function. Controls cell signaling pathways involved in glucose metabolism in skeletal muscle.

1. Taylor, KM. et al. (2004) The Biochemical journal 377, 131-9. PMID: 14525538
2. Huang, L. et al. (2005) The Journal of biological chemistry 280, 15456-63. PMID: 15705588
3. Nimmanon, T. et al. (2017) Metallomics : integrated biometal science 9, 471-481. PMID: 28205653
4. Woodruff, G. et al. (2018) Molecular pharmacology 94, 1092-1100. PMID: 29980658
5. Taylor, KM. et al. (2012) Science signaling 5, ra11. PMID: 22317921
6. Anzilotti, C. et al. (2019) Nature immunology 20, 350-361. PMID: 30718914
7. Fauster, A. et al. (2019) Cell death and differentiation 26, 1138-1155. PMID: 30237509
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Lebrikizumab Non-Neutralizing Recombinant Antibody |抗来瑞珠单抗非中和重组抗体(靶标:来瑞珠单抗非中和抗体) 610
Anti-Lebrikizumab Non-Neutralizing Recombinant Antibody |抗来瑞珠单抗非中和重组抗体(靶标:来瑞珠单抗非中和抗体) 585
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 667
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 538
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 562
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 535
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 466
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 396
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 367
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 443
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 290
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 354
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 383
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 371
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 530
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 423
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 607
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 523
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 396
Anti-Sarilumab Non-Neutralizing Recombinant Antibody|抗萨瑞鲁单抗非中和重组抗体(靶标:萨瑞鲁单抗非中和抗体) 653
总计 33037 个记录,共 1652 页,当前第 1646 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00